Abstract:Background Epstein Barr virus (EBV) is a highly prevalent herpesvirus worldwide and its infection is associated with malignancies such as nasopharyngeal cancer (NPC), gastric cancer, lymphoepithelioma cancer and lymphoproliferative disorders. Virus-specific T (VST) cell therapies using T cells reactive against EBV have shown limited efficacy in clinical trials with several practical limitations such as the long preparation period and the variations of pre-existing EBV-reactive T cells in different donors. To overcome these technical constraints of the VST approach, we have established the genetically engineered T cells targeting EBV antigens with lentiviral transduction. A proof-of-concept clinical validation was further conducted against EBV+ malignancies (trial No. ChiCTR2100044497). Methods T cells were activated by CD3/CD28 stimulation, lentivirally transduced with codon-optimized CAR (targeting EBV envelope protein) or TCR (targeting EBV latent membrane protein) and further expanded ex vivo. Transgene expression and the T cell phenotype were assessed by flow cytometry. In vitro anti-tumor efficacy was analyzed by IFN-γ ELISA and killing assays such as RTCA Xcelligence. In vivo, the antitumor efficacy of EBV-specific T cells was evaluated in immunocompromised mice bearing human tumor xenografts. Anti-tumor responses in lymphoma and NPC were evaluated by Lugano 2014 and RECIST 1.1 respectively. Results T cells lentivirally transduced with EBV antigen-specific CAR or TCR demonstrated satisfactory surface expression of the introduced receptor and showed increased cytokine production when stimulated to target expressing tumor cells in vitro (figure 1). We have identified the TCRs against EBV latent membrane protein with high functional avidity as determined by peptide dose-response functional assays. In vitro cytotoxicity assays demonstrated strong killing of antigen positive tumor cell lines of the engineered EBV-specific CAR-T or TCR-T cells, while sparing the antigen-negative cells, indicating the specific T cell response. The single intravenous infusion of engineered EBV-specific T cells also led to dose-dependent anti-tumor responses in immunocompromised mouse xenograft models (figure 1). In the clinical trial, two patients with lymphoproliferative disease and one patient with advanced NPC treated with engineered EBV-targeting T cells experienced sustained objective responses. Moreover, in the NPC patient, the EBV DNA copy number decreased from 3.32*103 copies/ml at baseline to normal (<5.00*102 copies/ml) 2 months post infusion. The infused cells also demonstrated satisfactory safety profile with no neurotoxicity and ≥ Grade 2 cytokine release syndrome observed. Conclusions Our data demonstrate the feasibility of using genetically engineered T cells targeting EBV antigens such as envelope protein or latent membrane protein to treat EBV-associated malignancies. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100044497 Ethics Approval All animal studies were conducted at Guangzhou Regenerative Medicine and Health, Guangdong Laboratory as approved by IACUC (2020125). The clinical study was approved by the first affiliated hospital of Zhengzhou University's Ethics Board (L2021-Y027–005).

TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

328 Preclinical Analyses and Proof of Concept Clinical Study of Epstein Barr Virus (EBV) Specific Genetically Modified T Cells Against EBV Associated Malignancies

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial

An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model

Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma

A phase 2 Randomised Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients

Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.

A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients

Ex Vivo Expansion of Tumor-Infiltrating Lymphocytes from Nasopharyngeal Carcinoma Patients for Adoptive Immunotherapy.

Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies

Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study

Recombinant Humanised Anti-Pd-1 Monoclonal Antibody (js001) Treatment for Patients with Refractory or Metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label, Phase 1b/2, Clinical Study

Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma

Response-adapted Therapy for Locally Advanced Nasopharyngeal Carcinoma Based on Clinical Response and Circulating Epstein-Barr Virus DNA Level Post Induction Chemotherapy

Efficacy and Safety of QL1706, a Novel Dual Immune Checkpoint Blockade Containing a Mixture of Anti-Pd1 IgG4 and Anti-Ctla4 IgG1 Antibodies, for Advanced Nasopharyngeal Carcinoma (NPC): Pooled Cohort Data from Phase 1a/1b Trials.

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma

Functional Inactivation Of Ebv-Specific T-Lymphocytes In Nasopharyngeal Carcinoma: Implications For Tumor Immunotherapy